Effect of TCZ therapy and other confounding factors for the increase of Hb levels.

The effect size of TCZ therapy and other confounding factors for the increase of Hb levels after treatment was analyzed by the multivariate analysis of covariance. Disease activity and clinical response was assessed by CDAI and ΔCDAI in model 1, and CRP and ΔCRP in model 2, respectively. (ΔCDAI  =  CDAI at baseline – CDAI at week 12, ΔCRP  =  CRP at baseline – CRP at week 12). TCZ, tocilizumab; Hb, hemoglobin; LHD%, low hemoglobin density; CDAI, clinical disease activity index; CRP, C-reactive protein; mHAQ, modified health assessment questionnaire-disability index.

本研究采用多变量协方差分析，探究托珠单抗（tocilizumab，TCZ）治疗及其他混杂因素对治疗后血红蛋白（hemoglobin，Hb）水平升高的影响。模型1中采用临床疾病活动指数（clinical disease activity index，CDAI）及其变化值ΔCDAI评估疾病活动度与临床应答，模型2则分别采用C反应蛋白（C-reactive protein，CRP）及其变化值ΔCRP。其中ΔCDAI=基线CDAI - 12周时CDAI，ΔCRP=基线CRP - 12周时CRP。TCZ即托珠单抗（tocilizumab）；Hb即血红蛋白（hemoglobin）；LHD%即低血红蛋白密度；CDAI即临床疾病活动指数（clinical disease activity index）；CRP即C反应蛋白（C-reactive protein）；mHAQ即改良健康评估问卷-残疾指数（modified health assessment questionnaire-disability index）。